Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

@article{Saroufim2014ComparingBM,
  title={Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.},
  author={Maya Saroufim and Robert H. Habib and Rita Gerges and Jad F Saab and Asif Loya and Samir S Amr and Salwa Shabbir Sheikh and Mohammad Satti and Christian Oberkanins and Ibrahim Khalifeh},
  journal={Experimental and molecular pathology},
  year={2014},
  volume={97 3},
  pages={315-20}
}
BACKGROUND Selective BRAF inhibitors have shown dramatic results with regard to improving outcome in patients with melanoma. Testing the BRAF status in matched primary and metastatic melanomas to optimize individual targeted therapy is not well investigated. METHODS Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
5 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Comparing BRAF mutatio Implications on optimized targeted therapy

  • M Saroufim
  • Exp. Mol. Pathol
  • 2014
Highly Influential
4 Excerpts

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

  • L Boussemart
  • Ann. Oncol
  • 2013

Similar Papers

Loading similar papers…